4.68 USD
↗ 0.14 (3.08%)AT CLOSE (11:59 AM EDT)
Prelude Therapeutics Incorporated (PRLD) trades at $4.67 per share. The stock presents a mixed profile: our models indicate a Strong Buy for technical indicators, while underlying fundamentals flash a Sell. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Furthermore, PRLD is currently richly valued, trading at a premium to sector peers across key valuation metrics.
Technical & fundamental data as of Aug 6, 2026.